在一项3期双盲、双模拟临床试验中，使用36项简短问卷调查评估接受奥玛环素或利奈唑胺治疗的急性细菌性皮肤和皮肤结构感染成人患者的健康相关生活质量。
Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial.
作者信息
Chitra Surya, Hinahara Jordan, Goss Thomas F, Gunter Kyle, LaPensee Kenneth
机构信息
Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Boston Healthcare Associates, Inc., Boston, Massachusetts, USA.
出版信息
Open Forum Infect Dis. 2021 Sep 8;8(10):ofab459. doi: 10.1093/ofid/ofab459. eCollection 2021 Oct.
Abstract
This analysis of data from a Phase 3 study of adults with acute bacterial skin and skin structure infections showed that successful oral treatment with omadacycline (n = 368) or linezolid (n = 367) was associated with improvement in health-related quality of life.
摘要
这项针对患有急性细菌性皮肤和皮肤结构感染的成年人的3期研究数据分析表明，用奥玛环素（n = 368）或利奈唑胺（n = 367）进行成功的口服治疗与健康相关生活质量的改善相关。
Zotero 插件